A196170 Stock Overview
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ALTEOGEN Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩300,500.00 |
52 Week High | ₩328,500.00 |
52 Week Low | ₩42,050.00 |
Beta | 1.25 |
11 Month Change | 13.83% |
3 Month Change | 61.65% |
1 Year Change | 547.63% |
33 Year Change | 327.76% |
5 Year Change | 3,259.63% |
Change since IPO | 9,963.26% |
Recent News & Updates
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution
May 25ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29Recent updates
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution
May 25ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability
Apr 13Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Feb 18Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?
Dec 27Shareholder Returns
A196170 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 2.7% | 3.2% | 2.9% |
1Y | 547.6% | 37.4% | 4.4% |
Return vs Industry: A196170 exceeded the KR Biotechs industry which returned 37.4% over the past year.
Return vs Market: A196170 exceeded the KR Market which returned 4.4% over the past year.
Price Volatility
A196170 volatility | |
---|---|
A196170 Average Weekly Movement | 11.4% |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A196170's share price has been volatile over the past 3 months.
Volatility Over Time: A196170's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 138 | Soon-Jae Park | www.alteogen.com |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
ALTEOGEN Inc. Fundamentals Summary
A196170 fundamental statistics | |
---|---|
Market cap | ₩15.96t |
Earnings (TTM) | ₩25.54b |
Revenue (TTM) | ₩121.09b |
625.0x
P/E Ratio131.8x
P/S RatioIs A196170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A196170 income statement (TTM) | |
---|---|
Revenue | ₩121.09b |
Cost of Revenue | ₩64.25b |
Gross Profit | ₩56.83b |
Other Expenses | ₩31.29b |
Earnings | ₩25.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 480.79 |
Gross Margin | 46.93% |
Net Profit Margin | 21.09% |
Debt/Equity Ratio | 0.5% |
How did A196170 perform over the long term?
See historical performance and comparison